Efficacy of immune checkpoint inhibitors for in-transit melanoma

Overview of attention for article published in Journal for Immunotherapy of Cancer, May 2020

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (98th percentile)

So far, Altmetric has seen 16 news stories from 16 outlets.

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

News provided by Provectus Biopharmaceuticals Inc. Dec 01, 2022, 7:00 AM ET 50% CR and 83% ORR by RECIST 1.1 criteria Rapid CRs…

50% CR and 83% ORR by RECIST 1.1 criteria Rapid CRs achieved within 15 to 27 weeks Median PFS not reached during 2-year…

50% CR and 83% ORR by RECIST 1.1 criteria Rapid CRs achieved within 15 to 27 weeks Median PFS not reached during 2-year…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity, including 12 additional news stories.